posted on 2024-02-22, 00:08authored byShannon HedtkeShannon Hedtke, Anusha KodeAnusha Kode, Tony O Ukety, Jöel L Mande, Germain M Abhafule, Anuarite A Raciu, Claude B Uvon, Stephen R Jada, An Hotterbeekx, Joseph Nelson Siewe Fodjo, Makedonka Mitreva, Wilson Sebit, Robert Colebunders, Warwick GrantWarwick Grant, Annette C Kuesel
WHO and endemic countries target elimination of transmission of Onchocerca volvulus, the parasite causing onchocerciasis. Population genetic analysis of O. volvulus may provide data to improve the evidence base for decisions on when, where, and for how long to deploy which interventions and post-intervention surveillance to achieve elimination. Development of necessary methods and tools requires parasites suitable for genetic analysis. Based on our experience with microfilariae obtained from different collaborators, we developed a microfilariae transfer procedure for large-scale studies in the Democratic Republic of Congo (DRC) comparing safety and efficacy of ivermectin, the mainstay of current onchocerciasis elimination strategies, and moxidectin, a new drug. This procedure is designed to increase the percentage of microfilariae in skin snips suitable for genetic analysis, improve assignment to metadata, and minimize time and materials needed by the researchers collecting the microfilariae. Among 664 microfilariae from South Sudan, 35.7% and 39.5% failed the mitochondrial and nuclear qPCR assay. Among the 576 microfilariae from DRC, 16.0% and 16.7% failed these assays, respectively. This difference may not only be related to the microfilariae transfer procedure but also to other factors, notably the ethanol concentration in the tubes in which microfilariae were stored (64% vs. ≥75%).
Funding
This research was funded by the UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (WHO/TDR), grant numbers B80149 and B80153, and the National Institute of Allergy and Infectious Diseases (NIAID), grant number R01AI144161. The epidemiological studies in South Sudan from which microfilariae were provided for this research were funded by the European Research Council (ERC 671055). The clinical studies MDGH-MOX-3001 and MDGH-MOX-3002 in DRC, during which the microfilariae transfer procedure described here is used and from which some of the microfilariae used in this research were obtained, were funded by the EDCTP (RIA2017NCT-1843), Medicines Development for Global Health, and the Luxembourg National Research (LNR) fund (Inter/Vaillant/2018).